Myricetin
CAS 529-44-2
Myricetin (CAS 529-44-2) is a pharmaceutical compound with 10 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 17643.85481707317 nM | 160 | - |
| - | Potency | 12164.307589285714 nM | 120 | - |
| - | GI50 | 45736.5895 nM | 60 | - |
| - | MIC | 135.76404761904763 ug.mL-1 | 42 | - |
| - | Ki | 12045.181818181818 nM | 22 | - |
| - | EC50 | 31596.0255 nM | 20 | - |
| - | IC50 | 20.81416666666667 ug.mL-1 | 12 | - |
| - | AC50 | 8035.3341666666665 nM | 8 | - |
| - | Kd | 113.41666666666667 nM | 3 | - |
| - | MIC | 1550000 nM | 1 | - |
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| CYP1A1 CYP1A1 |
Inhibition | 6.429999828338623 pKi | 21482471 |
| CYP1B1 CYP1B1 |
Inhibition | 7.570000171661377 pKi | 21482471 |
| DNA topoisomerase II alpha TOP2A |
Inhibition | 6.409999847412109 pIC50 | - |
| Insulin receptor INSR |
Inhibition | 5.590000152587891 pKi | 3164998 |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Myricetin used for in pharmaceutical contexts?
Myricetin (CAS 529-44-2) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Myricetin?
No adverse-event association or SIDER side-effect rows are rendered for Myricetin in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Myricetin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Myricetin with EU status "permitted".
What clinical phase is Myricetin in?
No phase 1-4 clinical development badge is rendered for Myricetin because the matched compound identifier rows do not contain a max-phase value.